Department of Cardiology, Queen Alia Heart Institute, Royal Medical Services, Amman, Jordan.
Med Arch. 2021 Feb;75(1):56-60. doi: 10.5455/medarh.2021.75.56-60.
Cardiac implantable electronic devices - PM, ICD, and CRTs- are well-proven life-sustaining and the ultimate destination for many heart conditions. Based on scientific evidence, there is a worldwide incremental increase in CIED implantations numbers.
Early infection of cardiac implantable electronic devices (CIED)- pacemaker (PM), implantable cardioverter-defibrillator (ICD), and cardiac resynchronization therapy (CRT)- is a growing health challenge. We examined the effectiveness of antibiotic prophylaxis and treatment of early infection of CIED in a single center.
This is a retrospective, single-center observational study. Data were collected from patients' records from July 2017-July, 2019. All Patients received intravenous ceftriaxone 2gm before incision, Gentamicin 120mg pocket irrigation, and oral Amoxicillin/Clavulanate for 5 days post-implantation.
A 639 consecutive CIED implantations - PM (n=474, mean age, 64yr, female=49%), ICD (n=106, mean age 56yr, female=17%) and CRT (n=59, mean age, 54yr, female=20%)- were performed over 3years. The incidence of early infection was 1.9% (12 cases), female=41%. PM=5/474, ICD=5/106, and CRT=2/59. Three out of the 12 patients had total device explant due to pocket abscess; one PM had a generator changed; one ICD who had a pneumothorax, and the third one had reimplantation after ICD lead perforation. Nine cases were managed conservatively using saline dressing and oral Amoxicillin/Clavulanate, 3/9 patients developed a hematoma, 4/9 patients developed purulent suture line infection. None of them had infection recurrence on three months follow up.
Early infection of CIED is a rare complication with multiple predisposing factors. Our protocol is reassurance and prompt initiation of management protocol to prevent and treat this issue's sequences.
心脏植入式电子设备 - 起搏器 (PM)、植入式心律转复除颤器 (ICD) 和心脏再同步治疗 (CRT) - 已被证明可维持生命,是许多心脏疾病的最终治疗选择。基于科学证据,全球心脏植入式电子设备 (CIED) 的植入数量呈递增趋势。
心脏植入式电子设备 (CIED) - 起搏器 (PM)、植入式心律转复除颤器 (ICD) 和心脏再同步治疗 (CRT) - 的早期感染是一个日益严峻的健康挑战。我们在单一中心检验了抗生素预防和治疗 CIED 早期感染的效果。
这是一项回顾性、单中心观察性研究。数据来自 2017 年 7 月至 2019 年 7 月间患者的病历记录。所有患者在切开前均接受静脉注射头孢曲松 2 克、庆大霉素 120 毫克囊袋冲洗,以及术后 5 天口服阿莫西林/克拉维酸钾。
在 3 年时间里,我们共进行了 639 例连续的 CIED 植入手术 - PM(n=474,平均年龄 64 岁,女性占 49%)、ICD(n=106,平均年龄 56 岁,女性占 17%)和 CRT(n=59,平均年龄 54 岁,女性占 20%)。早期感染的发生率为 1.9%(12 例),女性占 41%。PM 为 5/474,ICD 为 5/106,CRT 为 2/59。12 例早期感染患者中有 3 例因囊袋脓肿而完全取出设备;1 例 PM 更换了发生器;1 例 ICD 出现气胸,第 3 例因 ICD 导线穿孔而重新植入。9 例患者采用盐水敷料和口服阿莫西林/克拉维酸钾保守治疗,其中 3/9 例出现血肿,4/9 例出现脓性缝线感染。在三个月的随访中,均未发现感染复发。
CIED 的早期感染是一种罕见的并发症,有多种诱发因素。我们的方案是提供保证,并及时启动管理方案,以预防和处理这一问题。